MedTrace Logo

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

NCT00722046 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 198

Last updated 2022-11-07

Study results available
· View outcomes & findings →

Summary

Purpose of the study is to determine whether multiple dose administration of PF-04360365 is safe and well tolerated in patient with mild to moderate Alzheimer's disease.

Conditions

Interventions

BIOLOGICAL

PF-04360365 0.1 mg/kg

0.1 mg/kg every 60 days (10 doses total)

BIOLOGICAL

PF-04360365 0.5 mg/kg

0.5 mg/kg every 60 days (10 doses total)

BIOLOGICAL

PF-04360365 1 mg/kg

1 mg/kg every 60 days (10 doses total)

DRUG

Placebo

Placebo every 60 days (10 doses total)

BIOLOGICAL

PF-04360365 3 mg/kg

3 mg/kg every 60 days (10 doses total)

BIOLOGICAL

PF-04360365 8.5 mg/kg

8.5 mg/kg every 60 days (10 doses total)

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-05
Primary Completion
2011-08-16
Completion
2011-08-16

Countries

  • United States
  • Australia
  • Belgium
  • Canada
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00722046 on ClinicalTrials.gov